Case of reactive sacroiliitis possibly induced by an mRNA coronavirus disease vaccine.
Nicolas RouxSophie PoussingFrançois MaurierPublished in: BMJ case reports (2022)
A woman in her 30s received a second dose, first booster, Corminaty vaccine against the SARS-CoV-2. Three days later, the patient developed unilateral sacroiliitis. A pelvic scan revealed inflammatory joint edges, bone erosion and a heterogeneous mass of 2.5 cm in the psoas muscle. Joint puncture revealed no microcrystalline deposits, but bone marrow cells, erythroblast were identified. The standard bacterial cultures and culture for mycobacteria were negative. HLA B27 was negative, and no seroconversion was identified for HIV, Epstein-Barr virus, cytomegalovirus, chlamydia or Quantiferon. Two months later, the sacroiliitis resolved.The aetiologic approach of this erosive unilateral acute sacroiliitis in a person naïve to rheumatologic pathology was negative for inflammatory or infectious sacroiliitis. Arthralgias after vaccination are expected. Arthritis is less common, and acute sacroiliitis has not yet been described. Acute sacroiliitis may be considered a reactive sacroiliitis to the anti-COVID-19 mRNA vaccine.
Keyphrases
- epstein barr virus
- sars cov
- coronavirus disease
- liver failure
- bone marrow
- respiratory failure
- drug induced
- respiratory syndrome coronavirus
- computed tomography
- diffuse large b cell lymphoma
- case report
- hepatitis c virus
- human immunodeficiency virus
- mesenchymal stem cells
- magnetic resonance imaging
- antiretroviral therapy
- hepatitis b virus
- binding protein
- hiv testing
- ultrasound guided